NCT02875223 2025-04-20
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
Celgene
Phase 1 Terminated
Clinical Trials
14 trialsNCT04537715 2025-02-19
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels
Ipsen
Phase 1 Completed
NCT05602597 2024-03-06
HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI
Hutchmed
Phase 1 Completed
NCT05720767 2023-03-01
HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study
Hutchmed
Phase 1 Completed
NCT00585195 2023-02-08
PROFILE 1001
Pfizer
Phase 1 Completed
NCT02253420 2020-12-14
COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients
Bayer
Phase 1 Completed
NCT01324323 2019-11-25
Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer
Celgene
Phase 1 Completed
NCT01844583 2019-03-25
Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib
Takeda
Phase 1 Completed
NCT01121133 2017-11-21
A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax
AbbVie
Phase 1 Completed
NCT01454076 2017-11-01
Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma
Takeda
Phase 1 Completed
NCT01950364 2016-05-11
A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
Millennium Pharmaceuticals, Inc.
Phase 1 Completed
NCT01026415 2014-12-18
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
Seagen Inc.
Phase 1 Completed
NCT01969682 2014-05-26
A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199
AbbVie
Phase 1 Withdrawn
NCT00608907 2012-01-30
An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)
Millennium Pharmaceuticals, Inc.
Phase 1 Completed